Evidence map›Paper›PMID 35203781›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Repurposing

Ahmad J Almalki, Tarek S Ibrahim, Sameh S Elhady, Khaled M Darwish, Wael A H Hegazy

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Disclosing New Insights on Pyrazolo[3,4-Journal of microbiology and biotechnology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Assessing the antibacterial potential of 6-gingerol: Combined experimental and computational approaches.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  10. Article
  11. Article
  12. Thymoquinone is a natural antibiofilm and pathogenicity attenuating agent inFrontiers in cellular and infection microbiology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Clinical Resistant Strains ofAntibiotics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ahmad J AlmalkiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-1333-980X
Tarek S IbrahimDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-3049-4617
Sameh S ElhadyDepartment of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-3799-0581
Khaled M DarwishDepartment of Medicinal Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.ORCID 0000-0002-0597-482X
Wael A H HegazyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0001-5683-4803
King Abdulaziz University · SASuez Canal University · EGZagazig University · EG

Funding

Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia IFPRC-007-166-2020
6 · The paper itself

Abstract

Antimicrobial resistance is among the world's most urgent public health problems. Diminishing of the virulence of bacteria is a promising approach to decrease the development of bacterial resistance. Quorum sensing (QS) systems orchestrate the bacterial virulence in inducer-receptors manner. Bacteria can spy on the cells of the host by sensing adrenergic hormones and other neurotransmitters, and in turn, these neurotransmitters can induce bacterial pathogenesis. In this direction,

Indexed as

bacterial virulencePseudomonas aeruginosaquorum sensingterazosinα-adrenoreceptor blockers

Identifiers

PMID35203781
PMCPMC8868568
OpenAlexW4210269370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.